PanTheryx Technology

Our approach:
Learning from nature.

We believe the most promising molecules to develop into medicines are found conserved among living systems, where millions of years of adaptive evolution have selected for safe and effective molecules that can be further enhanced into therapeutics.

These include the molecules keeping us healthy throughout our life, such as:

PanTheryx Technology

Our approach:
Learning from nature.

We believe the most promising molecules to develop into medicines won’t be created in a lab, but found conserved among living systems, where millions of years of adaptive evolution have already selected for molecules with superior efficacy and safety that can be further enhanced into therapeutics.

These include the molecules keeping us healthy throughout our life, such as:

Antibodies

Molecules which fend off pathogens.

Examples: IgG, IgA, IgM, IgD, IgE, IgY

Gut healing factors

Direct the restoration of gut lining tissue and microvilli.

Examples: TGFα, TGFβ, EGF, IGF-1, IGF-II, VEGF, PDGF

Gut microbiome modulating factors

Promote the growth of beneficial bacteria that can maintain gut health.

Example: Oligosaccharides

Augmenting the biologic activity of these building blocks through our technology platform

While these classes of molecules contribute to maintaining our health every day, they’re far from able to keep us perfectly healthy — natural evolutionary mechanisms that have directed their activity haven’t been able to keep up with the evolution of modern life. The biology of our bodies is slower to change than our diet and lifestyle, and this mismatch is largely responsible for the explosion of acute and chronic disease we face today — from metabolic disease to infections by C. difficile.

PanTheryx takes the approach that we can not only use these molecules as a backbone for new products, but that we can harness the power of the same evolutionary principles to augment their activity and address some of the most challenging disease states of the 21st century.

Our product candidates are:

Multi-molecule

Instead of developing a single molecule with one mechanism of action, we develop biologics with a single bioactive backbone that contains multiple molecules and multiple mechanisms of action working synergistically.

Shaped by evolutionary selection

The foundational molecules of our biologics have been created through millions of years of selective pressure, and their activity is further refined through selective pressure introduced through our technology platform.

Optimized with targeted activity to address multifactorial disease states

The underlying etiology of many diseases is often a result of multiple factors, with contributions from multiple sources such as pathogen exposure, immune dysregulation, and imbalance in commensurate microbiota.

Acting in the most promising frontier for new medicines: the gut

There are 69 trillion cells in the human body, but less than half are human.The rest are 39 trillion bacteria that live alongside the human cells, in addition to other microbes. Up until recently, we’ve largely ignored this microbiome — literally more than half of what constitutes the human body.

The human microbiome consists of over 10,000 microbial species expressing over 8 million protein-coding genes. These microbes play a central role in an array of bodily functions and overall health, so much so that the human microbiome is referred to as our second genome.

Yet expression of those 8 million genes is tightly regulated, all in a single place in the human body: The gut. Containing over 99% of the human microbiome, new research is showing that the gut is a key regulator of physiological function ranging from regulating inflammation and immunity to even things like mood, sleep and stress.

Humans evolved with microbes for millions of years, and the gut is where both human and microbial cells interact to modulate our systemic biology. Because of its many roles, the gut is arguably the most promising target for developing new medicines in the 21st century.